Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients.
Safdar
A
A
Department of Infectious Diseases, Infection Control and Employee Health, MD Anderson Cancer Center, Houston, TX, USA. asafdar@mdanderson.org
D000998:Antiviral Agents / Q000276:immunology / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D029121:Metapneumovirus / Q000187:drug effects* / Q000276:immunology; D018184:Paramyxoviridae Infections / Q000188:drug therapy* / Q000276:immunology; D012254:Ribavirin / Q000276:immunology / Q000627:therapeutic use*
D000998:Antiviral Agents; D012254:Ribavirin